This law mandates substitution of a less expensive product if the physician signs the prescription for an eligible brand name drug on the line marked "substitution permissible. " We purchased drugs by brand name and generically before the law went into effect. Later, we purchased the same drugs in the same stores using the formats "brand-dispense-as-written/ ' "brand-substitution-permissible/ ' and "generic. " Mean savings from generic prescribing or substitution increased from 1 2. 1 % ± 20.4 % before the law to 26.2 % ± 10.5% (brand-substitution-permissible) and 2 7. 2 % + 14.2% (generic). Prices for the same drug written the same way varied enormously among pharmacies. Brand-dispense-as-written, ...
• Spending on brand-name prescription medications, particularly brand-name biologic drugs, continues...
Abstract Background In the United States (U.S.), large price increases for selected generic drugs ha...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharma...
Substitution of brand-name drugs with generic equiva-lents is an important issue with regard to the ...
State generic substitution laws permit, and sometimes require, a pharmacist to ignore the instructio...
The pharmaceutical industry has been among the most innovative while being one of the most highly re...
Generic drugs are copies of brand-name drugs that have exactly the same dosage, intended use, effect...
Generic prescribing and generic substitution are mechanisms for reducing the cost of drugs. The pur-...
We study the impact of product margins on pharmacies’ incentive to promote generics instead of brand...
The present paper evaluates the quantitative impact of a pharmaceutical reform on pharmaceutical pr...
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every y...
The government and health authorities have a duty to provide safe, effective and efficient health ca...
Purpose: To estimate the willingness and ability of private plans to manage costs during the generic...
The impact of a systematic generic substitution and of the new drug pricing system (implemented in 2...
OBJECTIVE: To describe the history of generic prescription pricing programs at major pharmacy chains...
• Spending on brand-name prescription medications, particularly brand-name biologic drugs, continues...
Abstract Background In the United States (U.S.), large price increases for selected generic drugs ha...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharma...
Substitution of brand-name drugs with generic equiva-lents is an important issue with regard to the ...
State generic substitution laws permit, and sometimes require, a pharmacist to ignore the instructio...
The pharmaceutical industry has been among the most innovative while being one of the most highly re...
Generic drugs are copies of brand-name drugs that have exactly the same dosage, intended use, effect...
Generic prescribing and generic substitution are mechanisms for reducing the cost of drugs. The pur-...
We study the impact of product margins on pharmacies’ incentive to promote generics instead of brand...
The present paper evaluates the quantitative impact of a pharmaceutical reform on pharmaceutical pr...
Background: As in other societies, pharmaceutical expenditures in the Netherlands are rising every y...
The government and health authorities have a duty to provide safe, effective and efficient health ca...
Purpose: To estimate the willingness and ability of private plans to manage costs during the generic...
The impact of a systematic generic substitution and of the new drug pricing system (implemented in 2...
OBJECTIVE: To describe the history of generic prescription pricing programs at major pharmacy chains...
• Spending on brand-name prescription medications, particularly brand-name biologic drugs, continues...
Abstract Background In the United States (U.S.), large price increases for selected generic drugs ha...
In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharma...